WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...

In August, a team of mathematicians posted a paper claiming to solve a major problem in algebraic geometry — using entirely alien techniques. It instantly captivated the field, stoking excitement in ...

Chris Wedel is a fan of all things tech and gadgets. Living in rural Kansas with his wife and two young boys makes finding ways to stay online tricky — not to mention making my homestead smarter.

The average one-year price target for Replimune Group (NasdaqGS:REPL) has been revised to $12.82 / share. This is an increase of 10.52% from the prior estimate of $11.60 dated November 14, 2025. The ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min CEO Bill Witte, who has been at ...

All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Gizmodo may earn an affiliate commission. Reading time 7 minutes ...

Marika Taylor currently receives funding from EPSRC, STFC, UK government deparments and the European Horizon programme. In 1980, Stephen Hawking gave his first lecture as Lucasian Professor at the ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the ...

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Replimune ...

The fate of a once-promising cancer treatment now looks uncertain at best. The meeting was conducted with U.S. Food and Drug Administration (FDA) officials, and it took place on Tuesday. The subject ...

or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit ...